Unlock instant, AI-driven research and patent intelligence for your innovation.
Use of loganin in the preparation of antitumor drugs
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of logan aglycone and its application, applied in the field of medicine, can solve problems such as the anti-tumor biological activity or clinical application research of no logan aglycone, and achieve the effects of reducing the economic burden, improving the quality of life and obvious anti-tumor effect.
Active Publication Date: 2021-07-20
SHANDONG NEWTIME PHARMA
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0008] So far, there is no research on the anti-tumor biological activity or clinical application of loganinin
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0024] Example 1 Loganin Tablets
[0025]
[0026] Preparation process: mix loganin, microcrystalline cellulose and sodium carboxymethyl starch evenly, add appropriate amount of starch slurry to make soft material, and pass through a 16-mesh sieve to granulate. The wet granules are dried at 60°C, the dry granules are passed through a 20-mesh sieve for granulation, the fine powder in the dry granules is screened out, mixed with magnesium stearate, and then mixed with the dry granules, pressed into tablets, each tablet is about 200mg, that is, .
Embodiment 2
[0027] Example 2 Loganinin Capsules
[0028] Loganin 10g
[0029] Microcrystalline Cellulose 300g
[0030] Micronized silica gel 12g
[0031] Preparation process: pulverize loganin, microcrystalline cellulose, and micropowder silica gel, pass through a 100-mesh sieve, mix well, and directly fill capsules.
Embodiment 3
[0032] Example 3 Loganinin Granules
[0033]
[0034] Preparation process: weigh the loganin, starch, dextrin, and sucrose powder in the prescribed amount and mix them evenly. Add an appropriate amount of 80% ethanol to the mixed powder, mix evenly, make a soft material, pass through a 18-mesh nylon sieve to make wet granules, dry at about 60°C, granulate with a 20-mesh sieve, and pack separately.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the field of medicine and relates to the use of loganin in the preparation of antitumor drugs. The tumors described herein specifically relate to mammalian gastric cancer, liver cancer, esophageal cancer, colorectal cancer, pancreatic cancer, lung cancer, head and neck cancer, leukemia , malignant lymphoma, prostate cancer, breast cancer, glioma, cholangiocarcinoma, melanoma, kidney cancer, ovarian cancer, endometrial cancer, cervical cancer, more specifically human gastric cancer, human liver cancer, human esophageal cancer, human node cancer Rectal cancer, human pancreatic cancer, human lung cancer, human head and neck cancer, human leukemia, human malignant lymphoma, human prostate cancer, human breast cancer, human glioma, human cholangiocarcinoma, human melanoma, human kidney cancer, human ovary carcinoma, human endometrial carcinoma, and human cervical carcinoma. Through in vivo and in vitro tests, it is found that loganin has a good inhibitory effect on the above-mentioned various tumors, shows good anti-tumor growth activity, and has great potential to be developed as an anti-tumor drug.
Description
technical field [0001] The invention belongs to the field of medicine, and in particular relates to the use of loganin in the preparation of antitumor drugs. Background technique [0002] Malignant tumors are diseases in which cell DNA suddenly mutates under certain conditions, resulting in uncontrolled cell division, resulting in continuous proliferation and metastasis, and finally leading to the death of the host. At present, the clinically available treatment methods for malignant tumors include surgery, radiotherapy, hyperthermia, chemotherapy, gene therapy, and immunotherapy. While the prior art has shown that it is possible to treat malignancies within a limited capacity using different techniques and treatments, these techniques and treatments all have some significant disadvantages. For example, chemotherapy as the main treatment method not only has limited anti-tumor effect, but also has relatively high toxicity and side effects, poor patient tolerance and high pri...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.